An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer. (18th February 2019)

• Record Type: Journal Article
• Authors: Feins, Steven; Kong, Weimin; Williams, Erik F.; Milone, Michael C.; Fraietta, Joseph A.
• Other Names: Frey Noelle V. guestEditor.; Porter David L. guestEditor.
• Is Part Of: American journal of hematology. Volume 94(2019)Supplement 1
• Page Start: S3
• Page End: S9
• Publication Date: 2019-02-18
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25418
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract : Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR T cells are then expanded for clinical use and infused back into the patient's body to attack and destroy chemotherapy‐resistant cancer. Dramatic clinical responses and high rates of complete remission have been observed in the setting of CAR T‐cell therapy of B‐cell malignancies. This resulted in two recent FDA approvals of CAR T cells directed against the CD19 protein for treatment of acute lymphoblastic leukemia and diffuse large B‐cell lymphoma. Thus, CAR T cells are arguably one of the first successful examples of synthetic biology and personalized cellular cancer therapy to become commercially available. In this review, we introduce the concept of using CAR T cells to break immunological tolerance to tumors, highlight several challenges in the field, discuss the utility of biomarkers in the context of predicting clinical responses, and offer prospects for developing next‐generation CAR T cell‐based approaches that will improve outcome.